A
Alwin D. R. Huitema
Researcher at Utrecht University
Publications - 431
Citations - 11143
Alwin D. R. Huitema is an academic researcher from Utrecht University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 50, co-authored 366 publications receiving 8994 citations. Previous affiliations of Alwin D. R. Huitema include University Medical Center Utrecht & Netherlands Cancer Institute.
Papers
More filters
Journal ArticleDOI
Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Ron J. Keizer,Alwin D. R. Huitema,Jan H.M. Schellens,Jan H.M. Schellens,Jos H. Beijnen,Jos H. Beijnen +5 more
TL;DR: The parenteral administration, slow tissue distribution and long elimination half-life are the most pronounced clinical pharmacokinetic characteristics of mAbs.
Journal ArticleDOI
Clinical Pharmacokinetics of Cyclophosphamide
TL;DR: Variations in the balance between metabolic activation and inactivation of cyclophosphamide owing to autoinduction, dose escalation, drug-drug interactions and individual differences have been reported, suggesting possibilities for optimisation of cyclphosphamide therapy.
Journal ArticleDOI
Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM
TL;DR: A graphical user interface, Piraña, was developed that offers a complete modeling environment for NONMEM, enabling both novice and advanced users to increase efficiency of their workflow.
Journal ArticleDOI
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
Remy B. Verheijen,Huixin Yu,Jan H.M. Schellens,Jos H. Beijnen,Neeltje Steeghs,Alwin D. R. Huitema +5 more
TL;DR: The available clinical pharmacokinetic and pharmacodynamic data is summarized into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM) and an overview of prospective TDM trials is provided.
Journal ArticleDOI
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Huixin Yu,Neeltje Steeghs,C.M. Nijenhuis,Jan H.M. Schellens,Jan H.M. Schellens,Jos H. Beijnen,Jos H. Beijnen,Alwin D. R. Huitema +7 more
TL;DR: The focus of this article is on the elaboration of exposure and response relationships of TKIs with proposed pharmacokinetic targets, mainly Ctrough, and further on the interpretation of the pharmacokinetics targets with recommendations for dose titrations.